MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

Search

Perrigo Co PLC

Geschlossen

BrancheGesundheitswesen

26.93 -0.85

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

26.82

Max

27.21

Schlüsselkennzahlen

By Trading Economics

Einkommen

38M

-6.4M

Verkäufe

-94M

1B

Dividendenrendite

4.34

Gewinnspanne

-0.613

Angestellte

8,379

EBITDA

13M

127M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+26.15% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

4.34%

2.42%

Nächstes Ergebnis

1. Aug. 2025

Nächste Dividendenausschüttung

16. Sept. 2025

Nächstes Ex-Dividendendatum

29. Aug. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

414M

3.8B

Vorheriger Eröffnungskurs

27.78

Vorheriger Schlusskurs

26.93

Nachrichtenstimmung

By Acuity

46%

54%

39 / 376 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Strong Bullish Evidence

Perrigo Co PLC Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

14. Juli 2025, 13:01 UTC

Akquisitionen, Fusionen, Übernahmen

Perrigo to Sell Dermacosmetics Business to KKR With Focus on Streamlining Company

28. Feb. 2025, 17:42 UTC

Wichtige Markttreiber

Perrigo Shares Jump on FDA's Move to Reclassify Wisconsin Infant-Formula Plant

27. Feb. 2025, 23:52 UTC

Ergebnisse

Perrigo Gets Facility Reclassification From FDA as 4Q Profit, Revenue Fall

14. Juli 2025, 12:33 UTC

Akquisitionen, Fusionen, Übernahmen

Perrigo: Business Generated About 5% of 2024 Adjusted Operating Income >PRGO

14. Juli 2025, 12:33 UTC

Akquisitionen, Fusionen, Übernahmen

Perrigo: Dermacosmetics Branded Business Generated About EUR125 Million Sales in 2024 >PRGO

14. Juli 2025, 12:32 UTC

Akquisitionen, Fusionen, Übernahmen

Perrigo: Deal Proceeds to Further Strengthen Balance Sheet >PRGO

14. Juli 2025, 12:31 UTC

Akquisitionen, Fusionen, Übernahmen

Perrigo: Deal Includes EUR300 Million Upfront Cash, Up to EUR27 Million Contingent Payments >PRGO

14. Juli 2025, 12:31 UTC

Akquisitionen, Fusionen, Übernahmen

Perrigo To Sell Dermacosmetics Branded Business to KKR Investment Vehicle >PRGO

14. Juli 2025, 12:30 UTC

Akquisitionen, Fusionen, Übernahmen

Perrigo Announces Agreement to Divest Dermacosmetics Business for Up to EUR327 Million

Peer-Vergleich

Kursveränderung

Perrigo Co PLC Prognose

Kursziel

By TipRanks

26.15% Vorteil

12-Monats-Prognose

Durchschnitt 34.25 USD  26.15%

Hoch 42 USD

Tief 27 USD

Basierend auf 4 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Perrigo Co PLC – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

4 ratings

2

Buy

2

Halten

0

Sell

Technischer Score

By Trading Central

25.22 / 26.85Unterstützung & Widerstand

Kurzfristig

Strong Bullish Evidence

Mittelfristig

Strong Bullish Evidence

Langfristig

Bullish Evidence

Stimmung

By Acuity

39 / 376 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Perrigo Co PLC

Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. It also offers healthy lifestyle products, such as smoking cessation, well-being, and weight management products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women's health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; rare diseases business; and other miscellaneous self-care products. The company sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, Compeed Stops, XLS, Arterin, Davitamon, Apiserum, Abtei, and Nicorette brands. It also offers contract manufacturing services. The company sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.